SAN DIEGO, April 11, 2019 /PRNewswire/ -- Viking
Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
the presentation of new results from the company's 12-week Phase 2
study of VK2809, its novel liver-selective thyroid receptor beta
agonist, in patients with non-alcoholic fatty liver disease (NAFLD)
and elevated low-density lipoprotein cholesterol (LDL-C) at the
International Liver Congress™ 2019. The study
results were presented in the late-breaker poster session of the
annual meeting of the European Association for the Study of the
Liver (EASL), being held April 10-14
in Vienna, Austria.
Highlights from the late-breaker poster include newly reported
data demonstrating that all patients who received 5 mg of VK2809
dosed daily were considered responders, as defined by a relative
reduction in liver fat of ≥ 30% at Week 12. Patients in the
VK2809 5 mg cohort also experienced a statistically significant
median relative reduction in liver fat content of 53.8%.
Consistent with the observations from the 10 mg cohorts in this
study, VK2809 was shown to be safe and well tolerated when dosed at
5 mg daily, with no serious adverse events reported. Overall,
a greater proportion of VK2809-treated patients completed the study
compared with patients randomized to placebo.
Data presented at The International Liver Congress 2019
include:
Reduction in LDL-C
The study successfully achieved its primary endpoint, with
patients receiving VK2809 demonstrating statistically significant
reductions in LDL-C following 12 weeks of treatment. In
addition to LDL-C, VK2809-treated patients also demonstrated
statistically significant improvements in other lipids, including
triglycerides and the atherogenic proteins apolipoprotein B and
lipoprotein (a). These improvements suggest potential
cardiovascular benefit associated with VK2809 treatment.
Reduction in Liver Fat Content
The study successfully achieved its secondary endpoint, with
VK2809-treated patients experiencing statistically significant
reductions in liver fat content compared with placebo after 12
weeks of treatment. Newly reported data demonstrated that
100% of patients receiving 5 mg of VK2809 dosed daily were
considered responders, experiencing ≥ 30% relative reduction from
baseline in liver fat content at Week 12. With new data from
the study's 5 mg cohort, the overall responder rate for
VK2809-treated patients increased to 88%, compared to approximately
17% for patients randomized to placebo. Furthermore, the
study's 'super'-responder rate for VK2809-treated patients
increased to 70% when data from the 5 mg cohort are incorporated.
'Super'-responders are those patients who demonstrated ≥ 50%
reduction in liver fat content at 12 weeks. Overall, the
results from the 5 mg daily dosing cohort are comparable to
previously reported results for study patients receiving 10 mg
VK2809 dosed every other day or 10 mg VK2809 dosed daily for 12
weeks. Liver fat content was assessed by magnetic resonance
imaging, proton density fat fraction (MRI-PDFF).
|
Placebo
(n=12)
|
VK2809 5 mg
QD
(n=9)
|
VK2809 10 mg
QOD
(n=13)
|
VK2809 10 mg
QD
(n=11)
|
VK2809
combined
(n=33)
|
Median relative %
change in liver fat by MRI-PDFF
|
-9.4%
|
-53.8%
(p=0.0001)
|
-56.5%
(p=0.0018)
|
-59.7%
(p=0.0004)
|
-56.5%
(p<0.0001)
|
Mean absolute %
change in liver fat by MRI-PDFF
|
-1.1%
|
-8.7%
(p=0.014)
|
-8.9%
(p=0.013)
|
-10.6%
(p=0.0030)
|
-9.4%
(p=0.0007)
|
Percentage of
patients experiencing ≥ 30% reduction in liver fat
|
16.7%
|
100.0%
(p=0.0002)
|
76.9%
(p=0.0048)
|
90.9%
(p=0.0006)
|
87.9%
(p<0.0001)
|
Percentage of
patients experiencing ≥ 50% reduction in liver fat
|
16.7%
|
77.8%
(p=0.0092)
|
61.5%
(p=0.041)
|
72.7%
(p=0.012)
|
70.0%
(p=0.014)
|
Maximum observed
reduction
|
52.8%
|
77.9%
|
72.4%
|
75.6%
|
77.9%
|
Safety and Tolerability
VK2809 was shown to be safe and well tolerated at all doses
evaluated in this study. No serious adverse events (SAEs)
were reported among patients receiving either VK2809 or placebo.
The incidence of overall adverse events (AEs) and
treatment-emergent adverse events (TEAEs) were relatively evenly
distributed between patients receiving VK2809 compared with
patients receiving placebo. A greater proportion of
VK2809-treated patients completed the study compared with patients
receiving placebo and the rate of study discontinuation due to an
adverse event was similar for patients receiving either placebo or
VK2809.
Mean alanine aminotransferase (ALT) levels among patients
receiving VK2809 were reduced relative to those of patients
receiving placebo at Week 12. Among patients with elevated
ALT at baseline, those receiving VK2809 demonstrated even greater
reductions in mean ALT levels relative to placebo at Weeks
12. Mean aspartate aminotransferase (AST) levels among
VK2809-treated patients were also reduced relative to placebo at
Weeks 12. There were no clinically or numerically meaningful
differences in direct bilirubin, indirect bilirubin, alkaline
phosphatase, or international normalized ration (INR) between
patients treated with VK2809 or placebo.
VK2809 demonstrated encouraging cardiovascular safety in this
study. The proportion of VK2809-treated patients reporting a
CV-related AE was comparable to, though numerically lower than, the
proportion of placebo-treated patients reporting a CV-related AE.
No changes to cardiovascular toxicity markers such as
troponin, CK-MB, or NT-proBNP were observed among VK2809-treated
patients compared with placebo. Additionally, no clinically
meaningful changes to the thyroid hormone axis were observed among
VK2809-treated patients compared with placebo-treated patients.
VK2809 was also shown to be well-tolerated in this study,
with no differences in gastrointestinal-related adverse events
compared with placebo.
Based on these study results, Viking is preparing to initiate a
Phase 2b study of VK2809 in patients
with biopsy-confirmed non-alcoholic steatohepatitis (NASH), which
is anticipated to begin in the second half of 2019.
"The liver fat reductions produced by low-dose VK2809 are
impressive and may suggest improvement in histology in longer-term
biopsy-based studies. Our research suggests that reducing
liver fat by 30% or more increases the likelihood of a potential
histologic response in NASH patients. Since more than
two-thirds of patients receiving VK2809 demonstrated at least a 50%
reduction in liver fat we would expect a potentially higher
likelihood of improved liver histology," stated Rohit Loomba, M.D., MHSc, Director, NAFLD
Research Center, and Professor of Medicine, University of California at San Diego. "These
robust improvements in liver fat content, combined with reductions
in plasma lipids such as LDL-C suggest a potential cardioprotective
benefit in these patients, which would represent a promising and
novel profile."
"We are gratified that VK2809's robust efficacy is maintained at
doses as low as 5 mg daily. The results observed at 5 mg are
similar to those obtained at higher doses and support our
enthusiasm for VK2809's promise as a potential therapy for patients
with NASH. The totality of data suggests a differentiated
therapeutic profile, with the potential to improve liver health and
provide global benefits on systemic lipids such as LDL-C and
atherogenic proteins," stated Brian
Lian, Ph.D., chief executive officer of Viking. "We
are also encouraged by VK2809's preliminary safety and tolerability
profile, and in particular that no SAEs have been observed in any
study to date. In this Phase 2 study, the number of patients
completing treatment, reporting treatment-emergent AEs, and
discontinuing due to AEs all appear well-balanced between treatment
and placebo cohorts. Importantly, liver and cardiovascular
safety are promising, with mean ALT and AST levels reduced relative
to placebo and no evidence of changes observed to vital signs or
markers of cardiovascular safety. We look forward to
initiating our planned Phase 2b study
in patients with biopsy-confirmed NASH later this year."
Study Design
The Phase 2 study was a randomized, double-blind,
placebo-controlled, parallel-group study designed to evaluate the
efficacy, safety and tolerability of VK2809 in patients with
elevated LDL-C and NAFLD. Patients were randomized to receive
placebo, 5 mg VK2809 dosed daily, 10 mg VK2809 dosed every other
day, or 10 mg VK2809 dosed daily for 12 weeks. Completion of
enrollment of patients in the 5 mg cohort was deferred until
enrollment was complete in the 10 mg QD and 10 mg QOD arms.
The trial's primary endpoint assessed the effect of VK2809
treatment on LDL-C after 12 weeks compared to placebo. The
secondary endpoint evaluated changes in liver fat content by
MRI-PDFF in patients with a valid baseline and post-baseline
MRI.
About VK2809
VK2809 is an orally available, tissue and receptor-subtype
selective agonist of the thyroid beta receptor (TRβ) that possesses
selectivity for liver tissue, as well as the beta receptor subtype,
suggesting promising therapeutic potential in a range of lipid
disorders. The compound successfully achieved primary and secondary
endpoints in a Phase 2 study for the treatment of patients with
elevated LDL-C and non-alcoholic fatty liver disease (NAFLD).
VK2809 belongs to a family of novel prodrugs, which are cleaved
in vivo to release potent thyromimetics. Selective
activation of the TRß receptor in liver tissue is believed to
favorably affect cholesterol and lipoprotein levels via multiple
mechanisms, including increasing the expression genes associated
with lipid metabolism and clearance.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, including non-alcoholic steatohepatitis (NASH). In
a Phase 2 trial for the treatment of non-alcoholic fatty liver
disease (NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
Forward-Looking Statements
This press release contains forward-looking statements
regarding Viking Therapeutics, Inc., under the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, including statements about Viking's expectations regarding
its development activities, timelines and milestones, as well as
the company's goals and plans regarding VK2809 and its prospects.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially and adversely
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: risks associated with the success, cost and timing
of Viking's product candidate development activities and clinical
trials, including those for VK5211 and VK2809; risks that prior
clinical and preclinical results may not be replicated; risks
regarding regulatory requirements; and other risks that are
described in Viking's most recent periodic reports filed with the
Securities and Exchange Commission, including Viking's Annual
Report on Form 10-K for the year ended December 31, 2018, and subsequent Quarterly
Reports on Form 10-Q, including the risk factors set forth in those
filings. These forward-looking statements speak only as of the date
hereof. Viking disclaims any obligation to update these
forward-looking statements except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-presents-new-data-from-phase-2-study-of-vk2809-in-patients-with-non-alcoholic-fatty-liver-disease-nafld-and-elevated-ldl-cholesterol-at-the-international-liver-congress-2019-300830451.html
SOURCE Viking Therapeutics, Inc.